Inflammation and peripheral venous disease

Summary

The inflammatory response to healing in venous thrombosis might cause vein damage and post-thrombotic syndrome. Inflammation may also be involved in venous insufficiency apart from deep-vein thrombosis. We studied the association of inflammation markers with venous insufficiency in a general population sample. We characterised 2,404 men and women in a general population cohort for peripheral venous disease and its severity using physical exam, symptom assessment, and venous ultrasound. Inflammation markers, C-reactive protein (CRP), fibrinogen, interleukin 1-beta (IL-1-beta), IL-8, IL-10, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, monocyte chemoattractant-1 (MCP-1) and vascular endothelial cell growth factor (VEGF) were compared in 352 case participants with peripheral venous disease and 352 controls with no venous abnormalities frequency matched to cases by age, sex and race. Associations were also evaluated including a subset of 108 cases of severe venous disease, as previously defined. Odds ratios (95% CI), for peripheral venous disease for biomarkers in the top quartile (adjusting for age, race, sex, body mass index and history of venous thrombosis) were 1.8 (1.1–3.0), 1.6 (1.0–2.5) and 1.5 (0.9–2.3) for CRP, fibrinogen and IL-10, respectively. Associations were larger considering cases of severe venous disease, with odds ratios for these three analytes of 2.6 (1.2–5.9), 3.1 (1.3–7.3) and 2.2 (1.1–4.4), and for IL-8: 2.4 (1.1–5.2). There was no association of IL-1-beta, ICAM-1, VCAM-1, E-selectin, MCP-1 or VEGF with overall cases or severe venous disease. In conclusion, a subset of inflammation markers were associated with increased risk of peripheral venous disease, suggesting potential therapeutic targets for treatment.

Keywords

Inflammation - venous disease - venous insufficiency - risk factor

• References

• 1 Heit JA, Rooke TW, Silverstein MD. et al. Trends in the incidence of venous stasis syndrome and venous ulcer: a 25-year population-based study. J Vasc Surg 2001; 33: 1022-1027.
• 2 Kahn SR, Shrier I, Julian JA. et al. Determinants and time course of the post-thrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698-707.
• 3 Tracy RP, Psaty BM, Macy E. et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997; 17: 2167-2176.
• 4 McGuinness CL, Humphries J, Waltham M. et al. Recruitment of labelled monocytes by experimental venous thrombi. Thromb Haemost 2001; 85: 1018-1024.
• 5 Henke PK, Varga A, De S. et al. Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. Arterioscler Thromb Vasc Biol 2004; 24: 1130-1137.
• 6 Ali T, Humphries J, Burnand K. et al. Monocyte recruitment in venous thrombus resolution. J Vasc Surg 2006; 43: 601-608.
• 7 Downing LJ, Strieter RM, Kadell AM. et al. IL-10 regulates thrombus-induced vein wall inflammation and thrombosis. J Immunol 1998; 161: 1471-1476.
• 8 Myers Jr. DD, Hawley AE, Farris DM. et al. Cellular IL-10 is more effective than viral IL-10 in decreasing venous thrombosis. J Surg Res 2003; 112: 168-174.
• 9 Humphries J, McGuinness CL, Smith A. et al. Monocyte chemotactic protein-1 (MCP-1) accelerates the organisation and resolution of venous thrombi. J Vasc Surg 1999; 30: 894-899.
• 10 Henke PK, Pearce CG, Moaveni DM. et al. Targeted deletion of CCR2 impairs deep vein thombosis resolution in a mouse model. J Immunol 2006; 177: 3388-3397.
• 11 Henke PK, Wakefield TW, Kadell AM. et al. Interleukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res 2001; 99: 84-91.
• 12 Wojcik BM, Wrobleski SK, Hawley AE. et al. Interleukin-6: a potential target for post-thrombotic syndrome. Ann Vasc Surg 2011; 25: 229-239.
• 13 Waltham M, Burnand KG, Collins M. et al. Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi. J Vasc Surg 2000; 32: 988-996.
• 14 Waltham M, Burnand KG, Collins M. et al. Vascular endothelial growth factor enhances venous thrombus recanalisation and organisation. Thromb Haemost 2003; 89: 169-176.
• 15 Ripplinger CM, Kessinger CW, Li C. et al. Inflammation modulates murine venous thrombosis resolution in vivo: assessment by multimodal fluorescence molecular imaging. Arterioscler Thromb Vasc Biol 2012; 32: 2616-2624.
• 16 Cushman M, Callas PW, Denenberg JO. et al. Risk factors for peripheral venous disease resemble those for venous thrombosis: the San Diego Population Study. J Thromb Haemost 2010; 08: 1730-1735.
• 17 Allison MA, Cushman M, Callas PW. et al. Adipokines are associated with lower extremity venous disease: the San Diego population study. J Thromb Haemost 2010; 08: 1912-1918.
• 18 Criqui MH, Jamosmos M, Fronek A. et al. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. Am J Epidemiol 2003; 158: 448-456.
• 19 Langer RD, Ho E, Denenberg JO. et al. Relationships between symptoms and venous disease: the San Diego population study. Arch Intern Med 2005; 165: 1420-1424.
• 20 Fronek A, Criqui MH, Denenberg J. et al. Common femoral vein dimensions and hemodynamics including Valsalva response as a function of sex, age, and ethnicity in a population study. J Vasc Surg 2001; 33: 1050-1056.
• 21 Powell CC, Rohrer MJ, Barnard MR. et al. Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation. J Vasc Surg 1999; 30: 844-851.
• 22 Rohrer MJ, Claytor RB, Garnette CS. et al. Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of reflux. Cardiovasc Surg 2002; 10: 464-469.
• 23 Howlader MH, Smith PD. Symptoms of chronic venous disease and association with systemic inflammatory markers. J Vasc Surg 2003; 38: 950-954.
• 24 Shoab SS, Scurr JH, Coleridge-Smith PD. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - a pilot study. Eur J Vasc Endovasc Surg 1999; 18: 334-338.
• 25 Roumen-Klappe EM, Janssen MC, Van Rossum J. et al. Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study. J Thromb Haemost 2009; 07: 582-587.
• 26 Shbaklo H, Holcroft CA, Kahn SR. Levels of inflammatory markers and the development of the post-thrombotic syndrome. Thromb Haemost 2009; 101: 505-512.
• 27 Bouman AC, Smits JJ, Ten Cate H. et al. Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome. J Thromb Haemost 2012; 10: 1532-1538.